Keeping a leg artery open long-term without a permanent scaffold that could fracture under motion
The superficial femoral artery (SFA) and popliteal artery — together the "femoropopliteal segment" — supply blood to the leg below the groin. Unlike coronary arteries, this segment runs through tissue that flexes, compresses, and twists with every stride, squat, and stair climb. Peripheral artery disease (PAD) narrows this vessel with atherosclerotic plaque, causing claudication (exertional leg pain); treating it durably requires a strategy compatible with the vessel's unusual biomechanics.
Coronary artery stents live in a relatively protected mechanical environment — the heart contracts and relaxes, but a stented coronary segment does not bend sharply, compress axially, or twist through large angles. The femoropopliteal segment is the opposite case. As the leg moves through a normal gait cycle, sits, or crosses at the knee, the SFA and popliteal artery are subjected to four distinct deformation modes simultaneously: bending (flexion across the hip and knee, up to 40–70° at the knee alone), axial compression and elongation (the artery can shorten by roughly a fifth of its length during deep knee flexion, then re-lengthen), radial compression (external pressure from surrounding musculature, particularly at the adductor (Hunter's) canal and behind the knee), and torsion (rotation of up to 100° through a stride).
A rigid metal tube — a bare-metal or even a nitinol self-expanding stent — placed in this segment must absorb all four deformation modes, day after day, for the rest of the patient's life. Historically, first-generation femoropopliteal stents fractured at rates high enough to become a defined clinical entity ("stent fracture"), sometimes precipitating in-stent restenosis or occlusion at the fracture site. This biomechanical mismatch is the central reason interventionalists increasingly favor "leave nothing behind" strategies — angioplasty with or without a drug coating — over permanent scaffolding whenever the lesion characteristics allow it.
Early-generation nitinol stents in the femoropopliteal segment showed fracture rates as high as 20–65% in some cohorts by 2–3 years of follow-up, concentrated at the adductor canal and behind the knee — the exact zones of maximal flexion, compression, and torsion. This drove the "nothing left behind" philosophy behind drug-coated balloon development.
The biological cascade behind restenosis after balloon angioplasty is fundamentally the same in the leg as in the heart: barotrauma from balloon inflation injures the endothelium and stretches the arterial wall, triggering an acute elastic recoil (the vessel partially springs back toward its pre-treatment diameter within minutes to hours) followed by a slower neointimal hyperplasia response over the following weeks to months. Vascular smooth muscle cells migrate from the media into the intima, proliferate, and secrete extracellular matrix, progressively re-narrowing the lumen — the same fundamental process as in-stent restenosis in a coronary vessel.
What differs in the femoropopliteal segment are the lesion characteristics: peripheral lesions are typically far longer than coronary lesions (femoropopliteal disease commonly spans 5–25+ cm versus the 10–30 mm typical of a coronary lesion), more heavily and diffusely calcified, and more likely to include chronic total occlusions. Longer, more calcified lesions mean more total vessel wall injury, more neointimal tissue burden overall, and a proportionally greater impact from any strategy that successfully suppresses the proliferative response — which is exactly what a drug-coated balloon is designed to do.
Given the combination of high mechanical stress and long, calcified lesions, three broad revascularization strategies compete for the femoropopliteal segment: plain balloon angioplasty (POBA), balloon angioplasty followed by permanent stent placement, and drug-coated balloon (DCB) angioplasty without a permanent implant. POBA alone is simple and leaves nothing behind mechanically, but its results are limited by elastic recoil and unchecked neointimal hyperplasia. Stenting resists elastic recoil more effectively and can scaffold dissections, but introduces the durability risk described above. DCB angioplasty attempts to combine the mechanical simplicity of POBA — an open lumen achieved by expanding the vessel with no permanent hardware — with pharmacological suppression of the neointimal response, delivered locally during the same brief balloon inflation used to open the vessel.
Whether the interventionalist uses a plain balloon, a drug-coated balloon, or proceeds to stent placement, the immediate procedural goal is identical: mechanically dilate the stenotic or occluded segment to restore an adequate luminal diameter and re-establish antegrade blood flow to the limb. At this stage, all three strategies typically achieve comparable acute angiographic and hemodynamic success.
Balloon angioplasty works through controlled, deliberate arterial injury. A non-compliant or semi-compliant balloon catheter is advanced over a guidewire to the lesion and inflated to a defined pressure (typically 6–14 atmospheres, guided by the balloon's rated burst pressure and the lesion's resistance). Inflation compresses and fractures the atherosclerotic plaque, stretches the vessel wall circumferentially beyond its elastic limit, and frequently produces small, controlled dissections of the intima and media — these are expected and usually self-limited, contributing to the acute gain in luminal diameter.
For a drug-coated balloon, the mechanical step is identical, but the balloon surface carries a dose of antiproliferative drug (most commonly paclitaxel) embedded in a hydrophilic excipient coating. During the brief inflation — typically around 3 minutes, sometimes preceded by vessel preparation with a plain balloon or atherectomy device to optimize drug uptake — the coating transfers from the balloon surface to the vessel wall as the balloon contacts the freshly dilated, denuded intima. The mechanical result (an open lumen) is delivered in the same maneuver as the pharmacological payload.
Angiographically, a well-performed POBA, DCB, or stent procedure all produce a similar acute result: residual stenosis under roughly 30%, restored antegrade flow, and symptomatic relief of claudication in most patients within days. The drug coating on a DCB has essentially no effect on the acute mechanical gain — the antiproliferative payload does not begin altering the biology of the vessel wall until the following days to weeks, as it is slowly released from the tissue depot created during the single balloon inflation. This is precisely why DCB and POBA outcomes are indistinguishable immediately after the procedure and only begin to diverge once the restenosis cascade would otherwise start in the following stage.
A key procedural nuance: DCB efficacy depends heavily on adequate "vessel preparation" — pre-dilating heavily calcified or fibrotic lesions with a plain balloon (or debulking with atherectomy) before the drug-coated balloon is deployed, since drug transfer into the wall is poor if the lumen is not first adequately opened.
The weeks to months following angioplasty are the period when the fate of the treated segment is largely decided. Two overlapping processes threaten the acute gain achieved on the table: elastic recoil, which can begin within hours, and neointimal hyperplasia, which builds progressively over the following months — and which, left unchecked, is the dominant driver of femoropopliteal restenosis by 6–12 months.
Elastic recoil occurs because the arterial wall, especially its elastic media, tends to spring back toward its original diameter after the distending force of the balloon is removed. In the femoropopliteal segment, recoil can erase a meaningful fraction of the acute luminal gain within minutes to hours of balloon deflation, and is more pronounced in heavily calcified or fibrotic lesions that resist full plaque fracture. Recoil is a purely mechanical phenomenon — it is not affected by an antiproliferative drug coating, which is why stenting (a mechanical scaffold that physically resists recoil) has historically shown an advantage over POBA in the first weeks, even before biological restenosis has had time to develop.
Over the following weeks, balloon-induced injury to the endothelium and media triggers an inflammatory and proliferative cascade: platelets and inflammatory cells adhere to the denuded surface, growth factors (PDGF, FGF, TGF-β) are released, and vascular smooth muscle cells de-differentiate from a contractile to a synthetic phenotype, migrate from the media into the intima, proliferate, and deposit extracellular matrix. This neointimal tissue accumulates progressively, typically peaking in thickness around 3–6 months post-procedure, and — if unopposed — can renarrow the lumen enough to cause symptomatic restenosis or reocclusion.
Because femoropopliteal lesions are long and the vessel wall injury from angioplasty is extensive, the neointimal burden here tends to be substantially greater than in a typical coronary lesion. Historical series of plain balloon angioplasty in the femoropopliteal segment, without any antiproliferative strategy, report 12-month primary patency in roughly the 50–60% range — meaning close to half of treated vessels have already reoccluded or required reintervention by one year.
Elastic recoil and neointimal hyperplasia are mechanistically distinct: recoil is immediate and purely mechanical, while neointimal hyperplasia is a delayed biological response peaking months later. A drug-coated balloon targets only the second process — it does nothing to prevent recoil, which is one reason vessel preparation and adequate acute dilation still matter even when a DCB will be used.
Drug-coated balloon technology delivers a single, high local dose of an antiproliferative drug directly into the vessel wall during the brief balloon inflation, then relies on the drug's lipophilicity to remain resident in the tissue for weeks, suppressing the neointimal hyperplasia cascade throughout the highest-risk window — without leaving any permanent device in a vessel that will keep bending, compressing, and twisting for decades to come.
Paclitaxel is the dominant drug used on peripheral drug-coated balloons (an alternative, sirolimus and its analogues, is used on some newer devices). Paclitaxel is highly lipophilic and binds avidly to microtubules, disrupting the mitotic spindle and halting cell division — this makes it a potent antiproliferative agent against the migrating, dividing smooth muscle cells that build neointima. Crucially, paclitaxel's mechanism does not require continuous drug presence to remain effective: because it binds tightly and semi-irreversibly to tubulin, a single high-dose local exposure delivered during a few minutes of balloon contact can produce a durable antiproliferative effect lasting weeks to months in the tissue, long after the balloon itself has been removed from the body. This "one-shot" pharmacokinetic profile is what makes DCB technology feasible at all — it does not depend on a polymer or permanent scaffold slowly eluting drug over time, as a drug-eluting stent does.
Peripheral drug-coated balloons had to solve a formulation problem that differs from coronary drug-eluting stents: femoropopliteal vessels are considerably larger in diameter (typically 4–7 mm versus 2.5–4 mm for coronary vessels) and the lesions are much longer, meaning the total balloon surface area — and therefore the total drug payload delivered in one inflation — is much greater. Peripheral DCB coatings use a crystalline or amorphous paclitaxel formulation combined with a hydrophilic excipient (such as urea, in the IN.PACT platform, or iopromide, in other systems) that dissolves rapidly on contact with blood and tissue, allowing the paclitaxel crystals to adhere to and transfer into the injured vessel wall during the brief inflation rather than washing away downstream in the bloodstream. Coating uniformity, crystal size, and excipient choice all affect how efficiently drug is transferred to the wall versus lost to the circulation — differences between competing DCB platforms in these formulation details are part of why clinical trial results have not been perfectly uniform across devices.
Because the entire drug dose must transfer to the vessel wall in a single ~3-minute inflation, formulation science — crystal morphology, excipient solubility, and coating adhesion — is as important to a DCB's clinical performance as the choice of paclitaxel itself. Two DCBs delivering the same nominal dose can behave quite differently depending on how efficiently that dose actually reaches the tissue.
By the time the neointimal hyperplasia cascade would otherwise be peaking (roughly months 3–6 post-procedure, as described in Stage 3), the tissue-resident paclitaxel delivered by the DCB has already exerted its effect on the vascular smooth muscle cells attempting to migrate and proliferate in that window — arresting many of them before they can meaningfully contribute to lumen renarrowing. The result, seen consistently across DCB trials, is a lumen that stays substantially closer to its acute post-procedure diameter at 6, 12, and 24 months than a lumen treated with plain balloon angioplasty alone — achieved without any metal, polymer, or scaffold remaining in a vessel that will go on flexing at the hip and knee for the rest of the patient's life.
Multiple randomized controlled trials have compared drug-coated balloon angioplasty against plain balloon angioplasty in the femoropopliteal segment, consistently showing superior patency and lower reintervention rates with DCB. This evidence base — alongside a widely publicized 2018 safety signal and the subsequent studies that followed it — now shapes current clinical guidance on when to leave nothing behind.
Several pivotal randomized trials established the DCB patency benefit in the femoropopliteal segment. IN.PACT SFA (the IN.PACT Admiral DCB versus standard PTA) reported 12-month primary patency of 82.2% for DCB versus 52.4% for PTA, with the advantage persisting at 24 months (78.9% vs. 50.1%) and 5 years. LEVANT 2 (the Lutonix DCB) reported a smaller but still statistically significant advantage: 12-month primary patency of 65.2% for DCB versus 52.6% for PTA. Across these and other trials (ILLUMENATE, among others), the consistent pattern is a substantial reduction in clinically driven target lesion revascularization (repeat procedures) with DCB compared to plain balloon angioplasty, translating into meaningfully fewer reinterventions for patients over 1–2+ years of follow-up — without the stent fracture risk that accompanies a permanent metal scaffold in this segment.
In December 2018, a meta-analysis by Katsanos and colleagues, pooling randomized trial data on paclitaxel-coated devices (both DCBs and drug-eluting stents) in the femoropopliteal artery, reported an association between paclitaxel exposure and increased late (2- and 5-year) all-cause mortality compared to non-drug-coated devices — a signal that had not been apparent in the shorter-term data reported by the individual pivotal trials. This finding prompted an FDA warning in early 2019, paused enrollment in several ongoing trials, and led interventionalists worldwide to temporarily restrict paclitaxel device use, particularly in patients without critical limb ischemia.
Subsequent scrutiny — including FDA-mandated patient-level meta-analyses of individual trial data, large real-world registry studies (including Medicare claims analyses covering hundreds of thousands of patients), and post-hoc reanalyses accounting for differential loss to follow-up between trial arms — largely failed to replicate a causal mortality signal, and several analyses identified data and statistical artifacts (including disproportionate missing follow-up data in control arms) that could explain the original finding without invoking a true drug effect. By 2019–2020, the FDA had walked back the most restrictive elements of its warning while continuing to require updated product labeling and encouraging ongoing long-term safety surveillance.
The paclitaxel mortality controversy is a case study in the limits of aggregate meta-analysis: the original 2018 signal was statistically significant across pooled trials, yet no individual pivotal trial had shown it, no consistent dose-response relationship or plausible mechanism was established, and larger patient-level and real-world analyses did not confirm it. Current guidance treats paclitaxel DCBs as an appropriate option for suitable femoropopliteal lesions, with informed patient discussion and continued long-term follow-up data collection.
Contemporary guidelines and consensus documents generally favor a "leave nothing behind" approach — DCB angioplasty, with or without preceding debulking/atherectomy for vessel preparation — as a first-line strategy for many femoropopliteal lesions, reserving permanent stent placement for situations where DCB alone is insufficient: flow-limiting dissection after balloon angioplasty, elastic recoil that a balloon cannot control, or heavily calcified/long chronic total occlusions where adequate acute lumen gain cannot otherwise be achieved. When stenting is required, newer-generation nitinol stents with improved fatigue-resistant designs have reduced (though not eliminated) fracture rates relative to first-generation devices. The overarching principle — informed directly by the mechanical stresses unique to this anatomic segment — is to minimize permanent hardware in the femoropopliteal artery whenever the lesion and vessel anatomy allow it, using pharmacology rather than a scaffold to hold the biological restenosis response in check.